Product Description
Mechanisms of Action: Alkylating Agent
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral,Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: First Affiliated Hospital Xi'an Jiaotong University
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Colorectal Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| XJTU1AF2022SJ-XK005 | N/A |
Not yet recruiting |
Stem Cell Transplant |
2025-12-31 |
|
| CDR0000071312 | P3 |
Completed |
Colorectal Cancer |
None |